Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

This is the mantra of biologic manufacturer Codexis (NASDAQ: CDXS), which produces optimized enzymes to enhance the yield of current chemistry methods by traditional pharmaceutical companies. It was so focused on this effort that 51% of its revenue in 2012 was derived from a research and development collaboration with Royal Dutch Shell. When the agreement was terminated in August 2012, Codexis saw its full-year revenue melt from $88.3 million in 2012 to $31.9 million in 2013.